The distinction between phases and indications for therapy depends on serum HBV DNA and alanine aminotransferase (ALT) levels, the severity of liver disease and the presence of serological markers—HBeAg and hepatitis B surface antigen (HBsAg). Here, GPT is linked to liver disorder.